Fujisawa Pharmaceutical Company, Ltd.

Nobuharu Shigematsu

Masakuni Okuhara

Shigehiro Takase

Masami Ezaki

Masanori Okamoto

Hiroshi Hatanaka

Eisaku Tsujii

Satoshi Okada

Yasuhisa Tsurumi

Tohru Kino

Chiyoshi Kasahara

Motohiro Hino

Sumio Kiyoto

Motoaki Nishikawa

Akihiko Fujie

Kumiko Nitta

Toshiro Iwamoto

Hirokazu Tanaka

Kazuo Sakane

Kohji Kawabata

Seiji Hashimoto

Toshio Goto

Hidenori Ohki

Yasuhiro Hori

Naoki Fukami

Michizane Hashimoto

Kunio Nakahara

Takashi Fujita

Takanao Otsuka

Keiji Hemmi, Deceased

Yasuhiko Shinguh

Seiji Yoshimura

Noriaki Inamura

Hirotsugu Ueda

Yoshitada Notsu

Amino acid derivatives and their use as phospholipase A.sub.2 inhibitor

Cyclic peptide nuclei and derivatives thereof

A compound having antimicrobial activity of the following general formula: ##STR1## wherein R.sup.1 is hydrogen or hydroxy, R.sup.2 is hydrogen or hydroxy, R.sup.3 is hydroxy or hydroxysulfonyloxy, with proviso that when R.sup.1 is hydrogen, R.sup.2 is hydrogen, or a phamaceutically acceptable salt thereof. The compound can be used in a method for treating infectious diseases caused by pathogenic microorganism.

Antimicrobial polypeptide compound a pharmaceutical composition

The novel peptides WS-9326A, WS-9326B, their derivatives and pharmaceutically acceptable salts thereof have useful pharmacological activities, particularly in the treatment and/or prevention of asthma and/or pain. A method for the production of the peptides WS-9326A and WS-9326B and derivatives thereof using Streptomyces violaceoniger No. 9326 in a biologically pure form is described herein.

Process for producing WS-9326A and WS-9326B

A polypeptide compound having antimicrobial activity of the following general formula: ##STR1## wherein R.sup.1 is hydrogen or acyl group, R.sup.2 is hydroxy or acyloxy,

Polypeptide compound and a process for preparation thereof

A degenerative disease selected from the group consisting of cystic fibrosis, chronic bronchitis and bronchiectasia is treated by administering to a subject a therapeutically effective amount of WS7622A mono-or disulfate or pharmaceutically acceptable salt thereof.

WS7622A mono- or di-sulfate, process for preparation thereof and use

WS7622A mono- or di-sulfate and pharmaceutically acceptable salts thereof. WS7622A exhibits human leukocyte elastase-inhibiting activity.

WS7622A mono- or di- sulfate, process for preparation thereof and use

A method for therapy of disseminated intravascular coagulation, or chronic respiratory tract infectious disease characterized by administering to a patient in need thereof an effective dose suitable for therapeutic treatment of said condition of WS7622A mono- or di-sulfate ester or their pharmaceutically acceptable salt.

Prophylactic/therapeutic composition for disseminated intravascular

This invention relates to the novel peptides WS-9326A, WS-9326B, their derivatives and pharmaceutically acceptable salts thereof which have pharmacological activities, particularly in the treatment and/or prevention of asthma and/or pain.

Peptides WS-9326a and WS-9326b, derivatives thereof and uses thereof

A method of treating pulmonary emphysema or adult respiratory distress syndrome in a subject in need thereof which comprises administering to the subject an effective amount of WS7622A, B, C and/or D, derivatives thereof, or their pharmaceutically acceptable salt.

WS7622A, B, C and D substances, derivatives thereof, processes for

The present invention relates to new WS7622A, B, C and/or D substances, derivatives thereof and pharmaceutical compositions containing the new substances as active ingredients.

The invention relates to a compound having antimicrobial and antitumor activity, the compound being designated FR901228 substance of the following formula: ##STR1##

FR901228 substance and preparation thereof

Growing community of inventors

Tsukuba, Japan

Nobuharu Shigematsu